Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Incidence of skeletal related events in patients with bone metastasis receiving denosumab every four weeks compared to intervals greater than every four weeks.

Yerram P, Moore R, Wolf S, Barbour SY.

J Oncol Pharm Pract. 2019 Apr;25(3):529-534. doi: 10.1177/1078155217743074. Epub 2017 Dec 5.

PMID:
29207934
2.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH.

J Clin Oncol. 2017 Oct 1;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789. Epub 2017 Jul 31. Review.

PMID:
28759346
3.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
4.

Management of Patients With Chemotherapy-Induced Nausea and Vomiting.

Barbour SY.

J Adv Pract Oncol. 2017 Apr;8(3):303-308. Epub 2017 Apr 1. Review.

5.

Board-Certified Oncology Pharmacists: Their Potential Contribution to Reducing a Shortfall in Oncology Patient Visits.

Ignoffo R, Knapp K, Barnett M, Barbour SY, D'Amato S, Iacovelli L, Knudsen J, Koontz SE, Mancini R, McBride A, McCauley D, Medina P, O'Bryant CL, Scarpace S, Stricker S, Trovato JA.

J Oncol Pract. 2016 Apr;12(4):e359-68. doi: 10.1200/JOP.2015.008490. Epub 2016 Mar 22.

PMID:
27006358
6.

Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.

Goodin S, Barbour S, Song J, Berrak E, Cox D.

Am J Health Syst Pharm. 2015 Dec 15;72(24):2150-6. doi: 10.2146/ajhp140773.

PMID:
26637514
7.

Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment [Internet].

Abernethy AP, Coeytaux RR, Carson K, McCrory D, Barbour SY, Gradison M, Irvine RJ, Wheeler JL.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jan 29.

8.

Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis.

Morrow GR, Schwartzberg L, Barbour SY, Ballinari G, Thorn MD, Cox D.

J Community Support Oncol. 2014 Jul;12(7):250-8. doi: I 10.12788/jcso.0058.

9.

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).

Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D.

Support Care Cancer. 2014 Feb;22(2):469-77. doi: 10.1007/s00520-013-1999-9. Epub 2013 Oct 19.

10.

Corticosteroids in the treatment of chemotherapy-induced nausea and vomiting.

Barbour SY.

J Natl Compr Canc Netw. 2012 Apr;10(4):493-9. Review.

PMID:
22491048
11.

Antiemesis.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. No abstract available.

PMID:
22491046
12.

American College of Chest Physicians consensus statement on the use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy in adult patients.

Wahidi MM, Jain P, Jantz M, Lee P, Mackensen GB, Barbour SY, Lamb C, Silvestri GA.

Chest. 2011 Nov;140(5):1342-1350. doi: 10.1378/chest.10-3361.

PMID:
22045879
13.

Role of oncology clinical pharmacists in light of the oncology workforce study.

Sessions JK, Valgus J, Barbour SY, Iacovelli L.

J Oncol Pract. 2010 Sep;6(5):270-2. doi: 10.1200/JOP.000037.

14.

Antiemesis. Clinical Practice Guidelines in Oncology.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S.

J Natl Compr Canc Netw. 2009 May;7(5):572-95. No abstract available.

PMID:
19460282
15.

Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center.

Abernethy AP, Barbour SY, Uronis H, Zafar SY, Coan A, Rowe K, Pupa MR, Wheeler JL, Herndon JE 2nd.

Support Care Cancer. 2009 Jun;17(6):735-44. doi: 10.1007/s00520-008-0562-6. Epub 2008 Dec 19.

PMID:
19096882
16.

Caring for the treatment-experienced breast cancer patient: the pharmacist's role.

Barbour SY.

Am J Health Syst Pharm. 2008 May 15;65(10 Suppl 3):S16-22. doi: 10.2146/ajhp080090. Review.

PMID:
18463328
17.

A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer.

Riedel RF, Andrews C, Garst J, Dunphy F, Herndon JE 2nd, Blackwell S, Barbour S, Crawford J.

J Thorac Oncol. 2007 Jun;2(6):520-5.

Supplemental Content

Loading ...
Support Center